Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:can_be_used_to |
treatment of autoimmune diseases
|
| gptkbp:developed_by |
gptkb:Alexion_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
ALXN2060
|
| gptkbp:indication |
neurological disorders
|
| gptkbp:is_tested_for |
clinical trials
|
| gptkbp:mechanism_of_action |
complement inhibition
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:status |
investigational
|
| gptkbp:structure |
gptkb:monoclonal_antibody
|
| gptkbp:targets |
complement system
|
| gptkbp:bfsParent |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|